NCT05382546View on ClinicalTrials.gov

A Pharmacokinetic Study of Intravenous NTM-001 in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 23, 2022

Primary Completion Date

July 5, 2022

Study Completion Date

March 2, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

Ketorolac Tromethamine

Ketorolac tromethamine, alcohol free formulation, 1.0 mg/mL in saline solution (\~0.9% NaCl) adjusted to a pH of \~7.4. Contained in a sterile, polyolefin bag filled with 125 mL of NTM-001.

Trial Locations (1)

999077

HUK Phase 1 clinical trials center, Hong Kong

All Listed Sponsors
lead

Nuance Pharma (shanghai) Co., Ltd

INDUSTRY